LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1077-1083

  Yang, Yu ^a   Yang, Hua ^a   McNutt, Michael A ^a   Xiong, Fuxia ^a   Nie, Xiu ^b   Li, Li ^c   Zhou, Rouli ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Immunohistochemistry; Lysosome associated protein transmembrane 4 ; Ovarian carcinoma; Survival

Indexed keywords

LYSOSOME ASSOCIATED PROTEIN TRANSMEMBRANE 4BETA; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; LAPTM4B PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; BIOSYNTHESIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MEMBRANE PROTEINS; MIDDLE AGED; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149348651     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000112     Document Type: Article

References (22)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
2. Seidman JD and Kurman RJ: Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 17: 909-925, 2003.
3. Jemal A, Thomas A, Murray T and Thun M: Cancer statistics. CA Cancer J Clin 52: 23-47, 2002.
4. Ozols R, Rubin SC, Thomas GM and Robboy SJ: Principles and Practice of Gynecologic Oncology. 3rd edition, Lippincott Williams & Wilkins, Philadelphia, 2000.
5. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X and Ye DX: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22: 5060-5069, 2003.
6. Hogue DL, Nash C, Ling V and Hobman TC: Lysosome-associated protein transmembrane 4 alpha (LAPTM4 alpha) requires two tandemly arranged tyrosine-based signals for sorting to lysosomes. Biochem J 365: 721-730, 2002.
7. Hunziker W and Geuze HJ: Intracellular trafficking of lysosomal membrane proteins. Bioessays 18: 379-389, 1996.
8. He J, Shao G and Zhou R: Effects of the novel gene, LAPTM4B, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells. Beijing Da Xue Xue Bao 35: 348-352, 2003.
9. Liu J, Zhou R, Zhang N, Rui J and Jin C: Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J 113: 881-885, 2000.
10. Kasper G, Vogel A, Klaman I, Grone J, Petersen I, Weber B, Castanos-Velez E, Staub E and Mennerich D: The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 224: 93-103, 2005.
11. Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M, Rui JA and Ye DX: Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4β associated with hepatocellular carcinoma. World J Gastroenterol 10: 1555-1559, 2004.
12. Peng C, Zhou RL, Shao GZ, Rui JA, Wang SB, Lin M, Zhang S and Gao ZF: Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol 11: 2704-2708, 2005.
13. Morris DG, Musat M, Czirjak S, Hanzely Z, Lillington DM, Korbonits M and Grossman AB: Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol 153: 143-151, 2005.
14. Scully R: Histological typing of ovarian tumors. In: WHO International Classification of Tumours. Springer-Verlag, Berlin, 1999.
15. Benedet JL, Bender H, Jones H, Ngan HY and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70: 209-262, 2000.
16. Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B and Hauptmann S: Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160: 893-903, 2002.
17. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Kochli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G and Gastl G: High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86: 207-213, 2004.
18. Shigemasa K, Gu L, O'Brien TJ and Ohama K: Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res 9: 1756-1763, 2003.
19. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K and Tokuda M: Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21: 315-320, 2002.
20. Zhou L, He XD, Chen J, Cui QC, Qu Q, Rui JA and Zhao YP: Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer 43: 809-815, 2007.
21. Hogue DL, Kerby L and Ling V: A mammalian lysosomal membrane protein confers multidrug resistance upon expression in Saccharomyces cerevisiae. J Biol Chem 274: 12877-12882, 1999.
22. Liu X, Zhou R, Zhang Q, Zhang Y, Shao G, Jin Y, Zhang S, Lin M, Rui J and Ye D: Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene. Beijing Da Xue Xue Bao 35: 340-347, 2003.